| BCBS Montana Medical Policies | Rozanolixixumab-noli | 2025-12-15 |
| BCBS Montana Medical Policies | Surgical Treatments for Breast Cancer-Related Lymphedema | 2025-12-15 |
| BCBS Montana Medical Policies | Tocilizumab and Associated Biosimilar(s) | 2025-12-15 |
| BCBS Montana Medical Policies | Treatment of Congenital Athymia | 2025-12-15 |
| BCBS Montana Medical Policies | Ultrafiltration in Decompensated Heart Failure | 2025-12-15 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ostomy Supplies | 2025-12-15 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ocrelizumab (Ocrevus) | 2025-12-15 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Alemtuzumab (Lemtrada) | 2025-12-15 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ublituximab-xiiy (Briumvi) | 2025-12-15 |
| BCBS Highmark Penn Medicare Advantage | Ocrelizumab (Ocrevus) | 2025-12-15 |